BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

By WebmasterJuly 20, 2021November 1st, 2024No Comments

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

See more here

Previous PostAnnovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study
Next PostRide Health and the American Heart Association Partner to Improve Health Equity for Patients Facing Transportation Barriers

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostAnnovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study

Next PostRide Health and the American Heart Association Partner to Improve Health Equity for Patients Facing Transportation Barriers